Showing results (221-230 of 250) with videos related to
Sort By:
Pageof 25
European Journal of Endocrinology|June 12, 2025
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomasGerald Raverot, Pia Burman, Ana Paula Abreu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2019
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized GliomasPhilip Jonsson, Andrew L Lin, Robert J Young, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaAntonio Omuro, Kathryn Beal, Philip Gutin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2018
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic GliomasAntonio Omuro, Kathryn Beal, Katharine McNeill, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS LymphomaChristian Grommes, Subhiksha Nandakumar, Lauren R Schaff, et al.Neuro-Oncology|May 5, 2017
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendrogliomaAlissa A Thomas, Lauren E Abrey, Robert Terziev, et al.Neuro-Oncology|December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.The Journal of Clinical Endocrinology and Metabolism|March 20, 2025
Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumorsAndrew L Lin, Vasilisa Rudneva, Adam Newton, et al.Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.Pageof 25